SG11202001762RA - Anti-egfr antibody drug conjugates (adc) and uses thereof - Google Patents
Anti-egfr antibody drug conjugates (adc) and uses thereofInfo
- Publication number
- SG11202001762RA SG11202001762RA SG11202001762RA SG11202001762RA SG11202001762RA SG 11202001762R A SG11202001762R A SG 11202001762RA SG 11202001762R A SG11202001762R A SG 11202001762RA SG 11202001762R A SG11202001762R A SG 11202001762RA SG 11202001762R A SG11202001762R A SG 11202001762RA
- Authority
- SG
- Singapore
- Prior art keywords
- adc
- drug conjugates
- antibody drug
- egfr antibody
- egfr
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553837P | 2017-09-02 | 2017-09-02 | |
| PCT/US2018/049412 WO2019046859A1 (en) | 2017-09-02 | 2018-09-04 | ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001762RA true SG11202001762RA (en) | 2020-03-30 |
Family
ID=65526126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001762RA SG11202001762RA (en) | 2017-09-02 | 2018-09-04 | Anti-egfr antibody drug conjugates (adc) and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200188525A1 (he) |
| EP (1) | EP3675907A4 (he) |
| JP (1) | JP2020532523A (he) |
| KR (1) | KR20200041998A (he) |
| CN (1) | CN111295201A (he) |
| AU (1) | AU2018326878A1 (he) |
| BR (1) | BR112020004212A2 (he) |
| CA (1) | CA3073560A1 (he) |
| CL (1) | CL2020000508A1 (he) |
| CO (1) | CO2020003512A2 (he) |
| CR (1) | CR20200145A (he) |
| DO (1) | DOP2020000045A (he) |
| EC (1) | ECSP20020949A (he) |
| IL (1) | IL272920A (he) |
| MX (1) | MX2020002268A (he) |
| PE (1) | PE20200721A1 (he) |
| PH (1) | PH12020500417A1 (he) |
| RU (1) | RU2020112280A (he) |
| SG (1) | SG11202001762RA (he) |
| WO (1) | WO2019046859A1 (he) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220098242A1 (en) * | 2020-02-26 | 2022-03-31 | University Of Maryland, College Park | Compositions and methods for mucosal vaccination against sars-cov-2 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| KR20240112819A (ko) | 2021-09-30 | 2024-07-19 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 피롤로벤조디아제핀 유도체 및 이의 접합체, 이의 제조 방법 및 이의 응용 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2842895T3 (es) * | 2010-12-06 | 2021-07-15 | Seagen Inc | Anticuerpos humanizados contra LIV-1 y uso de los mismos para tratar el cáncer |
| PL2970512T3 (pl) * | 2013-03-12 | 2019-03-29 | Biocon Limited | Immunomodulujące białka fuzyjne i sposoby ich otrzymywania |
| PE20161211A1 (es) * | 2014-03-21 | 2016-11-27 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr |
| SI3129406T1 (sl) * | 2014-04-11 | 2019-04-30 | Medimmune, Llc | Konjugirane spojine, ki vsebujejo cisteinsko konstruirana protitelesa |
| KR102419766B1 (ko) * | 2014-05-22 | 2022-07-13 | 비온디스 비.브이. | 항체에 대한 링커 약물의 부위 특이적 접합 및 그 결과로 얻어지는 adc |
| CA3006738A1 (en) * | 2015-12-04 | 2017-06-08 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
-
2018
- 2018-09-04 AU AU2018326878A patent/AU2018326878A1/en not_active Abandoned
- 2018-09-04 EP EP18852236.1A patent/EP3675907A4/en not_active Withdrawn
- 2018-09-04 BR BR112020004212-9A patent/BR112020004212A2/pt not_active Application Discontinuation
- 2018-09-04 US US16/643,527 patent/US20200188525A1/en not_active Abandoned
- 2018-09-04 RU RU2020112280A patent/RU2020112280A/ru unknown
- 2018-09-04 KR KR1020207009274A patent/KR20200041998A/ko unknown
- 2018-09-04 MX MX2020002268A patent/MX2020002268A/es unknown
- 2018-09-04 CA CA3073560A patent/CA3073560A1/en not_active Abandoned
- 2018-09-04 CR CR20200145A patent/CR20200145A/es unknown
- 2018-09-04 PE PE2020000303A patent/PE20200721A1/es unknown
- 2018-09-04 WO PCT/US2018/049412 patent/WO2019046859A1/en active Application Filing
- 2018-09-04 CN CN201880070839.9A patent/CN111295201A/zh active Pending
- 2018-09-04 JP JP2020512352A patent/JP2020532523A/ja active Pending
- 2018-09-04 SG SG11202001762RA patent/SG11202001762RA/en unknown
-
2020
- 2020-02-26 IL IL272920A patent/IL272920A/he unknown
- 2020-02-26 DO DO2020000045A patent/DOP2020000045A/es unknown
- 2020-03-02 PH PH12020500417A patent/PH12020500417A1/en unknown
- 2020-03-02 CL CL2020000508A patent/CL2020000508A1/es unknown
- 2020-03-25 CO CONC2020/0003512A patent/CO2020003512A2/es unknown
- 2020-04-02 EC ECSENADI202020949A patent/ECSP20020949A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019046859A1 (en) | 2019-03-07 |
| CN111295201A (zh) | 2020-06-16 |
| CA3073560A1 (en) | 2019-03-07 |
| EP3675907A4 (en) | 2021-05-12 |
| EP3675907A1 (en) | 2020-07-08 |
| PH12020500417A1 (en) | 2021-03-01 |
| PE20200721A1 (es) | 2020-07-21 |
| BR112020004212A2 (pt) | 2020-09-08 |
| JP2020532523A (ja) | 2020-11-12 |
| RU2020112280A (ru) | 2021-10-05 |
| IL272920A (he) | 2020-04-30 |
| US20200188525A1 (en) | 2020-06-18 |
| MX2020002268A (es) | 2021-01-08 |
| CR20200145A (es) | 2020-08-03 |
| CL2020000508A1 (es) | 2020-07-10 |
| CO2020003512A2 (es) | 2020-06-19 |
| ECSP20020949A (es) | 2020-05-29 |
| KR20200041998A (ko) | 2020-04-22 |
| AU2018326878A1 (en) | 2020-03-19 |
| DOP2020000045A (es) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304717A (he) | תצמידי נוגדן כנגד cmet עם תרופה ושיטות לשימוש בהם | |
| IL265309A (he) | נוגדנים דו-ספציפיים נגד muc16 ו-cd3 ומצומדים תרופתיים נגד muc16 | |
| ZA201900059B (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| HK1257056A1 (zh) | 抗dll3抗體藥物綴合物以及使用方法 | |
| IL291073A (he) | תצמידים של תרופה של נוגדנים נגד egfr | |
| IL247936A0 (he) | נוגדנים כנגד egfr ותצמידי נוגדן תרופה | |
| IL267834A (he) | תצמידים של תרופה ונוגדן כנגד ccr7 | |
| IL268821A (he) | תצמידי תרופה נוגדן מבוססי- מעכבי hdac ושימוש בטיפול | |
| IL272920A (he) | תצמידים של תרופה של נוגדני egfr (adc) ושימושיהם | |
| EP3675908A4 (en) | ANTI-EGFR-DRUG (ADC) ANTIBODY CONJUGATES AND ASSOCIATED USES |